Monopar Therapeutics Ownership | Who Owns Monopar Therapeutics?

Monopar Therapeutics Ownership Summary

Monopar Therapeutics is owned by 45.39% institutional investors, 34.25% insiders, and 20.36% retail investors. Adage capital partners gp is the largest institutional shareholder, holding 8.56% of MNPR shares. iShares Russell 2000 ETF is the top mutual fund, with 1.55% of its assets in Monopar Therapeutics shares.

MNPR Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Monopar Therapeutics	45.39%	34.25%	20.36%
Sector	Healthcare Stocks	488.17%	11.08%	-399.26%
Industry	Biotech Stocks	306.68%	11.10%	-217.78%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Adage capital partners gp	599.20K	8.56%	$21.44M
Ra capital management	511.21K	7.30%	$18.29M
Blackrock funding, inc. /de	205.17K	2.93%	$7.34M
Point72 asset management	104.02K	1.49%	$3.72M
Adar1 capital management	100.97K	1.44%	$3.61M
Millennium management	194.30K	1.22%	$145.34K
Affinity asset advisors	67.50K	0.96%	$2.42M
Ally bridge group (ny)	34.54K	0.49%	$1.24M
Geode capital management	60.04K	0.38%	$44.91K
Virtu financial	18.84K	0.12%	$14.00K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Ally bridge group (ny)	34.54K	1.03%	$1.24M
Adar1 capital management	100.97K	0.55%	$3.61M
Affinity asset advisors	67.50K	0.33%	$2.42M
Ra capital management	511.21K	0.31%	$18.29M
Gerber	5.60K	0.14%	$200.40K
Adage capital partners gp	599.20K	0.04%	$21.44M
Point72 asset management	104.02K	0.01%	$3.72M
Virtu financial	18.84K	0.00%	$14.00K
Newedge advisors	600.00	0.00%	$21.47K
Millennium management	194.30K	0.00%	$145.34K

Top Buyers

Holder	Shares	% Assets	Change
Blackrock funding, inc. /de	205.17K	0.00%	190.71K
Ally bridge group (ny)	34.54K	1.03%	34.54K
Geode capital management	60.04K	-	18.84K
Affinity asset advisors	67.50K	0.33%	5.50K
Millennium management	194.30K	0.00%	1.92K

Top Sellers

Holder	Shares	% Assets	Change
Point72 asset management	104.02K	0.01%	-64.14K
Two sigma securities	-	-	-47.06K
Vanguard group	-	-	-45.17K
Marshall wace, llp	-	-	-25.99K
Rappaport reiches capital management	-	-	-10.70K

New Positions

Holder	Shares	% Assets	Change	Value
Ally bridge group (ny)	34.54K	1.03%	34.54K	$1.24M
Raymond james financial	431.00	-	431.00	$15.42K
Sterling capital management	10.00	-	10.00	$358.00

Sold Out

Holder	Change
Federation des caisses desjardins du quebec	-16.00
Point72 (difc)	-196.00
Tower research capital llc (trc)	-303.00
Morgan stanley	-800.00
Point72 asia (singapore) pte.	-1.76K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	43	26.47%	3,176,497	10.06%	45	266.08%	34	47.83%	4	-20.00%
Mar 31, 2025	34	88.89%	2,886,019	11.94%	4	8.93%	23	53.33%	5	400.00%
Dec 31, 2024	18	200.00%	2,578,295	16314.94%	6	341848.65%	15	1400.00%	1	-80.00%
Sep 30, 2024	6	-50.00%	15,707	-96.24%	-	16.30%	1	-83.33%	5	400.00%
Jun 30, 2024	12	-20.00%	418,162	5.80%	2	32.01%	6	-14.29%	1	-50.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
iShares Russell 2000 ETF	94.86K	1.55%	-1.78K
Vanguard Institutional Extnd Mkt Idx Tr	45.63K	0.74%	-11.02K
iShares Russell 2000 Growth ETF	37.34K	0.61%	-
Fidelity Extended Market Index	23.34K	0.38%	-61.00
Vanguard Russell 2000 ETF	19.36K	0.31%	-1.35K
State St Russell Sm Cap® Indx SL Cl I	14.30K	0.23%	-
Schwab Small Cap Index	10.25K	0.17%	-
NT R2000 Index Fund - NL	9.84K	0.16%	9.84K
iShares Micro-Cap ETF	9.29K	0.15%	-
Fidelity Total Market Index	8.00K	0.13%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jul 14, 2025	Tsuchimoto Kim R	-	Sell	$356.17K
Jul 14, 2025	STARR CHRISTOPHER M	-	Sell	$672.02K
Jul 14, 2025	Robinson Chandler	Chief Executive Officer	Sell	$672.02K
Apr 02, 2025	Tactic Pharma LLC	-	Sell	$1.17M
Oct 28, 2024	Radhakrishnan Karthik	Chief Financial Officer	Buy	$25.19K

Insider Transactions Trends

Date	Buy	Sell
2025 Q3	-	3
2025 Q2	-	1
2025 Q1	-	-
2024 Q4	1	-
2024 Q3	-	-

MNPR Ownership FAQ

Who Owns Monopar Therapeutics?

Monopar Therapeutics shareholders are primarily institutional investors at 45.39%, followed by 34.25% insiders and 20.36% retail investors. The average institutional ownership in Monopar Therapeutics's industry, Biotech Stocks , is 306.68%, which Monopar Therapeutics falls below.

Who owns the most shares of Monopar Therapeutics?

Monopar Therapeutics’s largest shareholders are Adage capital partners gp (599.2K shares, 8.56%), Ra capital management (511.21K shares, 7.30%), and Blackrock funding, inc. /de (205.17K shares, 2.93%). Together, they hold 18.80% of Monopar Therapeutics’s total shares outstanding.

Does Blackrock own Monopar Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Monopar Therapeutics.

Who is Monopar Therapeutics’s biggest shareholder by percentage of total assets invested?

Ally bridge group (ny) is Monopar Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.03% of its assets in 34.54K Monopar Therapeutics shares, valued at 1.24M$.

Who is the top mutual fund holder of Monopar Therapeutics shares?

iShares Russell 2000 ETF is the top mutual fund holder of Monopar Therapeutics shares, with 1.55% of its total shares outstanding invested in 94.86K Monopar Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools